|
|
(2 intermediate revisions not shown.) |
Line 1: |
Line 1: |
| | | |
| ==HIV-1 DIS kissing-loop in complex with ribostamycin== | | ==HIV-1 DIS kissing-loop in complex with ribostamycin== |
- | <StructureSection load='2fcz' size='340' side='right' caption='[[2fcz]], [[Resolution|resolution]] 2.01Å' scene=''> | + | <StructureSection load='2fcz' size='340' side='right'caption='[[2fcz]], [[Resolution|resolution]] 2.01Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[2fcz]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FCZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2FCZ FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[2fcz]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FCZ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2FCZ FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=RIO:RIBOSTAMYCIN'>RIO</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.01Å</td></tr> |
- | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=5BU:5-BROMO-URIDINE-5-MONOPHOSPHATE'>5BU</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5BU:5-BROMO-URIDINE-5-MONOPHOSPHATE'>5BU</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=RIO:RIBOSTAMYCIN'>RIO</scene></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2fcx|2fcx]], [[2fcy|2fcy]], [[1xp7|1xp7]], [[1y3s|1y3s]], [[2fd0|2fd0]]</td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2fcz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2fcz OCA], [https://pdbe.org/2fcz PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2fcz RCSB], [https://www.ebi.ac.uk/pdbsum/2fcz PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2fcz ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2fcz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2fcz OCA], [http://pdbe.org/2fcz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2fcz RCSB], [http://www.ebi.ac.uk/pdbsum/2fcz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2fcz ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 22: |
Line 21: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Dumas, P]] | + | [[Category: Large Structures]] |
- | [[Category: Ennifar, E]] | + | [[Category: Dumas P]] |
- | [[Category: Marquet, R]] | + | [[Category: Ennifar E]] |
- | [[Category: Paillart, J C]] | + | [[Category: Marquet R]] |
- | [[Category: Aminoglycoside]]
| + | [[Category: Paillart JC]] |
- | [[Category: Antibiotic]]
| + | |
- | [[Category: Hiv-1]]
| + | |
- | [[Category: Rna]]
| + | |
| Structural highlights
Publication Abstract from PubMed
The kissing-loop complex that initiates dimerization of genomic RNA is crucial for Human Immunodeficiency Virus Type 1 (HIV-1) replication. We showed that owing to its strong similitude with the bacterial ribosomal A site it can be targeted by aminoglycosides. Here, we present its crystal structure in complex with neamine, ribostamycin, neomycin and lividomycin. These structures explain the specificity for 4,5-disubstituted 2-deoxystreptamine (DOS) derivatives and for subtype A and subtype F kissing-loop complexes, and provide a strong basis for rational drug design. As a consequence of the different topologies of the kissing-loop complex and the A site, these aminoglycosides establish more contacts with HIV-1 RNA than with 16S RNA. Together with biochemical experiments, they showed that while rings I, II and III confer binding specificity, rings IV and V are important for affinity. Binding of neomycin, paromomycin and lividomycin strongly stabilized the kissing-loop complex by bridging the two HIV-1 RNA molecules. Furthermore, in situ footprinting showed that the dimerization initiation site (DIS) of HIV-1 genomic RNA could be targeted by these aminoglycosides in infected cells and virions, demonstrating its accessibility.
Targeting the dimerization initiation site of HIV-1 RNA with aminoglycosides: from crystal to cell.,Ennifar E, Paillart JC, Bodlenner A, Walter P, Weibel JM, Aubertin AM, Pale P, Dumas P, Marquet R Nucleic Acids Res. 2006 May 5;34(8):2328-39. Print 2006. PMID:16679451[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Ennifar E, Paillart JC, Bodlenner A, Walter P, Weibel JM, Aubertin AM, Pale P, Dumas P, Marquet R. Targeting the dimerization initiation site of HIV-1 RNA with aminoglycosides: from crystal to cell. Nucleic Acids Res. 2006 May 5;34(8):2328-39. Print 2006. PMID:16679451 doi:34/8/2328
|